HLB Co., Ltd. remains a rivoceranib approval story, while its small operating businesses cannot yet support the company's market value.
No news written yet.
| Period | 028300 | KOSDAQ | Difference |
|---|---|---|---|
| 1 week | -6.3% | -3.0% | -3.3% |
| 1 month | -1.7% | +4.2% | -5.9% |
| 3 months | -35.7% | -22.5% | -13.2% |
| 6 months | -26.1% | -16.9% | -9.3% |
| Year to date | -33.6% | -12.1% | -21.5% |
| 1 year | -14.4% | +1.0% | -15.5% |
Closed at 19% of the way from its 52-week low (₩25,650) to its 52-week high (₩68,200).
HLB is a Korean company whose central asset is rivoceranib, a cancer drug it has been pushing toward US approval for liver cancer in combination with a Chinese partner's immunotherapy. The FDA has issued rejections tied to manufacturing and inspection findings, and each resubmission moves the stock sharply. The company also holds a collection of affiliates in diagnostics and other health businesses. It draws unusually heavy attention from American retail investors for a company of its size.
| Sector | Biopharma | Employees | |
| Market | KOSDAQ | Founded | |
| Korean name | HLB | Head office |
| Symbol | Last Price |
|---|---|
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |